Our Recommendations
- Laboratory diagnosis of Buruli ulcer (2014)
- Diagnostic de l’ulcère de Buruli au laboratoire (2014)
- Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer) (2012)
- Buruli Ulcer Prevention of Disability (POD) (2006)
- Recognizing neglected tropical diseases through changes on the skin: a training guide for front-line health workers (2018)
New Publications
- NTDs Part 1: Buruli Ulcer, Chagas, Leishmaniasis (2024)
- Recent Advances in the Management Strategies for Buruli Ulcers (2023)
- Leishmaniasis - Prevention & Control (2020)
- Buruli Ulcer Disease: Obtaining Swab Specimens for Diagnosis of M. Ulcerans Infection - Youtube video (2023)
- Youtube: Buruli Ulcer (2023)
Filter
74
Featured
Recommendations
3
New Publications
2
Language
Document type
Studies & Reports
20
Guidelines
16
Manuals
7
Videos
7
Resource Platforms
6
Fact sheets
6
Brochures
5
Infographics
3
Training Material
1
Online Courses
1
Strategic & Response Plan
1
No document type
1
Countries / Regions
Global
16
Ghana
1
South–East Asia Region
1
East and Southern Africa
1
Authors & Publishers
Publication Years
Category
Buruli Ulcer
20
Bacteriology
3
Dermatology
3
Leishmaniasis
2
Online Courses & Platforms
1
x MEDBOX Issue Brief & Annual Reports x
1
Chagas
1
Guidelines
1
Information, Education and Communication (IEC)
1
Studies & Reports
1
NTDs & Others
1
Laboratory Technologies
1
Physiotherapy & Rehabilitation
1
Toolboxes
Clinical Aspects & Diagnostics
25
Information & Education Material (IEC)
25
Studies & Reports
17
Capacity Building & Resources
13
Disability Prevention & Rehabilitation
10
Statistics & Facts
8
MEDBOX Issue Brief no.35: The first issue brief on the NTD Toolbox contains general strategies, roadmaps, key treatment guidelines, reports, and training material on Buruli ulcer, Chagas, and Leishmaniasis.
Buruli ulcer (BU) is a bacterial skin infection that is caused by Mycobacterium ulcerans and mainly affects people who reside in the rural areas of Africa and in suburban and beach resort communities in Australia.
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with...
This course is intended to provide basic information for front-line health workers to be able to implement the recommended control measures to minimize the negative impact of Buruli ulcer on populations.
In 2013, WHO and the Foundation for Innovative New Diagnostics convened a meeting of Buruli ulcer experts in Geneva, Switzerland (9) at which two priority unmet needs in diagnosis were identified:
a diagnostic test for early detection of Buruli ulcer in symptomatic patients with sufficient positive...
Key facts
Buruli ulcer is a chronic debilitating disease caused by an environmental Mycobacterium ulcerans.
At least 33 countries with tropical, subtropical and temperate climates have reported Buruli ulcer in Africa, South America and Western Pacific regions.
It often affects the skin an...
Principaux faits
L’ulcère de Buruli est une infection chronique débilitante causée par la bactérie Mycobacterium ulcerans.
L’ulcère de Buruli a été signalé dans au moins 33 pays situés dans des régions au climat tropical, subtropical ou tempéré d’Afrique, d’Amérique ...
Datos y cifras
La úlcera de Buruli es una enfermedad crónica y debilitante causada por una micobacteria ambiental: Mycobacterium ulcerans.
Al menos 33 países de clima tropical, subtropical o templado han notificado casos de úlcera de Buruli en África, América del Sur y las regiones...
August 26, 2021
https://doi.org/10.1371/journal.pntd.0009678
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection....
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of...
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...
